At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24, 2020.
Nancy E. Davidson, MD, of the Seattle Cancer Care Alliance, and a member of The ASCO Post Editorial Board, talks about her experiences in one of the communities hardest hit by coronavirus and offers some practical advice on making changes in treatment and research. Recorded April 7, 2020.
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the challenges and concerns related to transplants for patients with hematologic malignancies who are particularly vulnerable to infection with the coronavirus. Recorded July 13, 2020.
William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and reviews best practices for treatment decisions, social distancing, and maintaining emotional health. Recorded April 15, 2020.
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.
